Eyetech Pharmaceuticals - Ownership and Business Overview

Life ScienceCompany

Eyetech Pharmaceuticals Ownership

Who owns Eyetech Pharmaceuticals?

Eyetech Pharmaceuticals is owned by Bausch Health Companies. It was acquired on March 1, 2012.

Eyetech Pharmaceuticals Business Overview

Where is Eyetech Pharmaceuticals headquartered?

Eyetech Pharmaceuticals is headquartered in Cedar Knolls, New Jersey.

What sector is Eyetech Pharmaceuticals in?

Eyetech Pharmaceuticals is a life science company.

Life Science M&A Summary in 2012

Out of 60 sectors in the Mergr database, life science ranked 18 in number of deals in 2012. The largest life science acquisition in 2012 was Amylin Pharmaceuticals - which was acquired by Bristol-Myers Squibb for $5.3B.

Join Mergr to view all 125 acquisitions of life science companies in 2012, including 18 acquisitions by private equity firms, and 107 by strategics.

Eyetech Pharmaceuticals, Inc.

140 East Hanover Avenue,
Cedar Knolls, New Jersey 07927
United States,
www.eyetech.com

Eyetech Pharmaceuticals was founded to discover and develop new drugs to reduce and prevent serious vision loss caused by eye disease. Eyetech's lead product, EYE001, addresses the two leading causes of blindness in the adult population-age-related macular degeneration (AMD) and diabetic macular edema (DME).


 Subscribe to unlock this and 209,180
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.6K Private Equity Firms
  • 202K M&A Transactions
  • 205K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.6K M&A Advisors
    (Investment Banks and Law Firms)
  • 81K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.